These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Roskoski R Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102 [TBL] [Abstract][Full Text] [Related]
26. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Lindauer K; Loerting T; Liedl KR; Kroemer RT Protein Eng; 2001 Jan; 14(1):27-37. PubMed ID: 11287676 [TBL] [Abstract][Full Text] [Related]
28. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892 [TBL] [Abstract][Full Text] [Related]
29. JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules. Newton AS; Deiana L; Puleo DE; Cisneros JA; Cutrona KJ; Schlessinger J; Jorgensen WL ACS Med Chem Lett; 2017 Jun; 8(6):614-617. PubMed ID: 28626520 [TBL] [Abstract][Full Text] [Related]
30. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations. Wan S; Coveney PV J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920 [TBL] [Abstract][Full Text] [Related]
31. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways. Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748 [TBL] [Abstract][Full Text] [Related]
32. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177 [TBL] [Abstract][Full Text] [Related]
33. Expression, characterization, and genomic structure of carp JAK1 kinase gene. Chang MS; Chang GD; Leu JH; Huang FL; Chou CK; Huang CJ; Lo TB DNA Cell Biol; 1996 Oct; 15(10):827-44. PubMed ID: 8892755 [TBL] [Abstract][Full Text] [Related]
34. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. Chang Y; Xu S; Ding K J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320 [TBL] [Abstract][Full Text] [Related]
35. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788 [TBL] [Abstract][Full Text] [Related]
36. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Roskoski R Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820 [TBL] [Abstract][Full Text] [Related]
37. On the regulation and activation of JAK2: a novel hypothetical model. Lee TS Mol Cancer Res; 2013 Aug; 11(8):811-4. PubMed ID: 23615525 [TBL] [Abstract][Full Text] [Related]
38. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors. Zhong HA; Almahmoud S Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004 [TBL] [Abstract][Full Text] [Related]